This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $591,752 to Oprems LLC to develop and assess a digital platform for screening patients prescribed opioid medications to identify risk of opioid misuse and overdose. The project aims to integrate Oprems' existing paper-based screening tools into a tablet-based digital platform to improve the consistency and effectiveness of opioid risk screening and...
This $594,122 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to develop and test workflows for delivering telehealth-based treatment for opioid use disorder (OUD) in high-risk settings. The award will fund a collaboration between Boulder Care, Inc., Sano Health, and the National Survivors Union to provide smartphones and connectivity to people in jails/prisons, emergency departments, residential treatment...
This Project Grant award, with a total funding amount of $958,629, was awarded by the National Institute on Drug Abuse (NIDA) under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The funding will support the real-world adoption of an innovative digital health therapeutic called KIOS, which uses nonlinear control theory to track multiple symptoms (e.g., craving, mood, pain) and deliver personalized, evidence-based intervention strategies to patients with opioid use disorder...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to discover novel small molecule therapeutics for safe and effective treatment of opioid use disorder (OUD). The $798,828 grant will fund the development of an AI-powered drug discovery platform called M3.AI, which will integrate target-based and phenotype-based approaches to identify multi-cell type and multi-target polypharmacological...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $586,936 to Vitan-Biotech LLC, a minority-owned biotechnology company, to develop a low-cost, disposable urine test strip for the rapid quantification of substance use disorder (SUD) medication drugs and their metabolites. The goal is to create a point-of-use diagnostic tool that can enable monitoring of medication compliance and metabolism for...
The U.S. National Institute on Drug Abuse (NIDA) awarded a $800,000 Cooperative Agreement grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Biosensics LLC, a digital health technology company, for the development of ODALERT - a wearable device designed to automatically detect and alert users and first responders of potential opioid overdoses. The project aims to complete the development, clinical validation, and regulatory approval process for ODALERT, which uses advanced...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will test a bundled intervention to increase treatment uptake for patients with opioid use disorder (OUD) after emergency department (ED) discharge. The $844,475 award, spanning September 2024 to August 2026, will first enroll 30 patients in a feasibility study (R61 phase) to assess the acceptability of the intervention. This intervention involves daily...
This $512,256 Project Grant from the National Institutes of Health's National Institute on Drug Abuse will support Health Outcomes Inc. doing business as Telesage to develop a Primary Care-SUD Intake System (P-SUD-IS). The P-SUD-IS aims to address underdiagnosis of substance use disorders (SUDs) by streamlining the SUD assessment process for primary care clinicians. Telesage will create a HIPAA-compliant, automated, cloud-based system to facilitate completion of biopsychosocial assessments for...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $319,278 to Photopharmics, Inc. to evaluate the use of a novel heterodyned whole body vibration (HWBV) device for treating opioid use disorder (OUD). The key objectives are to: 1) improve the technical aspects of the HWBV device, evaluate its effects on physiological markers of anxiety, and develop a prototype for FDA clearance; 2) assess blood...
This Project Grant award of $598,312 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support the integration and assessment of Addinex Technologies, Inc.'s closed-loop medication management system for opioid pain management in ambulatory patients with extremity fractures being discharged from the emergency department. The primary objectives are to: 1) adapt and enhance the Addinex system to align with hospital pharmacy...
BEACON-OUD: BEHAVIORAL ECONOMIC SCREENING TOOL OF OPIOID USE DISORDER FOR USE IN CLINICAL PRACTICE - PROJECT SUMMARY OPIOID USE DISORDER (OUD) IS A MAJOR CONTRIBUTOR TO EXCESSIVE DISABILITY, MORBIDITY, AND MORTALITY IN THE UNITED STATES. CURRENTLY, ALMOST 10 MILLION AMERICANS MISUSE OPIOID SUBSTANCES AND 2.7 MILLION AMERICANS SUFFER FROM OUD. IN THE PAST YEAR ALONE, U.S. OPIOID OVERDOSE DEATHS HAVE INCREASED BY NEARLY 30%, RESULTING IN AN ANNUAL MORTALITY RATE OF >100,000, AKIN TO A DEATH EVERY 5 MINUTES. GIVEN THE SCOPE OF THE U.S. OPIOID EPIDEMIC, THERE IS AN ESSENTIAL NEED FOR PROACTIVE, ROUTINE, EVIDENCE-BASED OUD SCREENING BY AN INDIVIDUAL'S PRESCRIBING PRIMARY CARE PROVIDER OR MENTAL HEALTH CLINICIANS. HOWEVER, SCREENING FOR OPIOID MISUSE IS UNDERPERFORMED, LABORIOUS, AND IS SUSCEPTIBLE TO DEMAND CHARACTERISTICS AND CONCERNS ABOUT STIGMATIZING THE PATIENT. TO COMBAT THESE ISSUES, BEAM DIAGNOSTICS, INC. DEVELOPED BEACON-OUD, A COMMERCIALIZABLE DIGITAL SCREENING TOOL FOR OUD. THE TOOL IS BASED ON THE THEORETICAL BEHAVIORAL FRAMEWORK OF REINFORCER PATHOLOGY, A WIDELY ADOPTED BEHAVIORAL ECONOMIC APPROACH TO ADDICTIVE BEHAVIOR. BEACON-OUD IS: (1) QUICK AND EASY-TO-DELIVER TO PATIENTS, WITH AUTOMATED, STANDARDIZED SCORING TO REDUCE TIME BARRIERS; (2) ACCESSIBLE, EASY-TO-COMPREHEND AND SELF- ADMINISTER; (3) NON-STIGMATIZING AND ASSESSES RISK WITHOUT DISCLOSING SENSITIVE INFORMATION; (4) ORIENTED TO CURRENT AND FUTURE, NOT PAST, OUD BEHAVIOR; AND 5) INTEROPERABLE AND INTEGRATED WITH A PATIENT'S MEDICAL RECORD TO IMPROVE THE STANDARDS FOR OUD ASSESSMENT AND PATIENT-CENTERED CARE. IN PHASE I OF THIS PROJECT, WE CONDUCTED A CLINICAL STUDY, VALIDATING BEACON-OUD AS DEMONSTRATING ROBUST PREDICTIVE ACCURACY OF OPIOID MISUSE AND RECEIVING POSITIVE REPORTS OF FEASIBILITY AND ACCEPTABILITY FROM PROVIDERS. THE GOAL OF THIS PHASE II SBIR IS TO EXTEND BEACON-OUD'S DEVELOPMENT INTO A FULLY REALIZED COMMERCIAL PRODUCT, BOTH AS A STAND-ALONE TOOL AND AS AN INTEGRATED TOOL WITHIN AN ELECTRONIC MEDICAL RECORD (EMR) SYSTEM AT A LARGE MULTI-SITE HEALTHCARE SYSTEM SERVING APPROXIMATELY 1M OUTPATIENTS PER YEAR. AIM 1 WILL OPTIMIZE THE USER-EXPERIENCE AND ACCESSIBILITY OF BEACON-OUD AS A PRODUCT, PRODUCE COMPREHENSIVE CLINICAL REFERENCE MATERIALS, AND COMPLETE A SPANISH- LANGUAGE TRANSLATION. AIM 2 WILL INTEGRATE BEACON-OUD INTO EPIC, A WIDELY USED ELECTRONIC MEDICAL RECORD SYSTEM WITHIN A HEALTH SYSTEM PARTNER TO IMPROVE USABILITY, WORKFLOW CAPABILITIES, AND RECORD-KEEPING OF OPIOID MISUSE DIRECTLY IN A PATIENT'S MEDICAL CHART. IN ADDITION, AIM 2 WILL LAUNCH EDUCATION AND IMPLEMENTATION INITIATIVES TO PROMOTE BEACON-OUD'S USE PRIMARY CARE. FINALLY, BEAM WILL COMPLETE AN EXPLORATORY AIM SEEKING TO VALIDATE AND EXPAND BEACON-OUD'S CLINICAL UTILITY AS A MEASUREMENT-BASED CARE TOOL FOR OUD TREATMENT PROGNOSIS. AT THE CONCLUSION OF THIS PHASE II PROJECT, BEAM WILL HAVE BROUGHT BEACON-OUD TO MARKET AS A DIGITAL ASSESSMENT FOR OUD MEASUREMENT, BOTH AS A STAND-ALONE PRODUCT AND AN EMR-INTEGRATED VERSION.